title: Involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in oxazolone-induced contact dermatitis in mice.
abstract: The possible involvement of 2-arachidonoylglycerol (2-AG), an endogenous ligand for the cannabinoid receptors (CB1 and CB2), in contact dermatitis in mouse ear was investigated. We found that the level of 2-AG was markedly elevated in the ear following a challenge with oxazolone in sensitized mice. Of note, the swelling following the challenge was suppressed by either the administration of SR144528, a CB2 receptor antagonist, immediately after sensitization, or the administration of SR144528 upon the challenge. The effect of AM251, a CB1 receptor antagonist, was marginal in either case. It seems apparent, therefore, that the CB2 receptor and its endogenous ligand 2-AG are closely involved in both the sensitization phase and the elicitation phase of oxazolone-induced contact dermatitis. In line with this, we found that Langerhans cells (MHC class II(+)) contain a substantial amount of CB2 receptor mRNA, whereas keratinocytes (MHC class II(-)) do not. We also obtained evidence that the expression of mRNAs for proinflammatory cytokines following a challenge with oxazolone was markedly suppressed by treatment with SR144528. We next examined whether the CB2 receptor and 2-AG participate in chronic contact dermatitis accompanied by the infiltration of tissues by eosinophils. The amount of 2-AG in mouse ear dramatically increased following repeated challenge with oxazolone. Importantly, treatment with SR144528 attenuated both the recruitment of eosinophils and ear swelling in chronic contact dermatitis induced by repeated challenge with oxazolone. These results strongly suggest that the CB2 receptor and 2-AG play important stimulative roles in the sensitization, elicitation, and exacerbation of allergic inflammation.
authors.affiliation: Faculty of Pharmaceutical Sciences, Teikyo University, Sagamihara, Kanagawa 199-0195, Japan.
authors.forename: Saori
authors.initials: S
authors.lastname: Oka
authors.forename: Junichi
authors.initials: J
authors.lastname: Wakui
authors.forename: Shinobu
authors.initials: S
authors.lastname: Ikeda
authors.forename: Shin
authors.initials: S
authors.lastname: Yanagimoto
authors.forename: Seishi
authors.initials: S
authors.lastname: Kishimoto
authors.forename: Maiko
authors.initials: M
authors.lastname: Gokoh
authors.forename: Miwako
authors.initials: M
authors.lastname: Nasui
authors.forename: Takayuki
authors.initials: T
authors.lastname: Sugiura
mesh_terms: D000818:Animals; D001095:Arachidonic Acids / Q000502:physiology*; D003877:Dermatitis, Contact / Q000209:etiology*; D004423:Ear; D063388:Endocannabinoids; D005989:Glycerides / Q000502:physiology*; D007249:Inflammation / Q000209:etiology; D015603:Keratinocytes; D007801:Langerhans Cells; D008024:Ligands; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D010081:Oxazolone / Q000494:pharmacology; D012333:RNA, Messenger / Q000032:analysis; D043885:Receptor, Cannabinoid, CB2 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*
chemical_list: D001095:Arachidonic Acids; D063388:Endocannabinoids; D005989:Glycerides; D008024:Ligands; D012333:RNA, Messenger; D043885:Receptor, Cannabinoid, CB2; D010081:Oxazolone; C094503:glyceryl 2-arachidonate